13F filing recap · Q3 2024
What did ArrowMark Partners buy in Q3 2024?
Reported stock-position changes between this filing and the previous one. US-listed stocks across every ArrowMark account, including accounts that belong to no fund below.
Stock value
$7.81B
Positions
301
Estimated turnover
25.8%
Turnover is a proxy: verified trade-origin share changes valued at period-end and divided by average reported stock value. SEC holdings reports do not disclose execution dates or prices. Corporate actions and unreconciled activity are excluded.
Quarter in review
ArrowMark Partners opened new positions in Globus Medical, First American Financial, Jbt Marel, Federal Signal, and Exact Sciences, among others. The firm exited Adt, Allete, Atmus Filtration Technologies, Avery Dennison, and Bel Fuse, along with several other holdings. It substantially trimmed Acv Auctions, Matson, Bio-Techne, Cimpress, Graphic Packaging, and Skechers, while adding to Waystar and Ncino.